BioCentury
ARTICLE | Politics, Policy & Law

R-e-l-i-e-f is spelled e-l-e-c-t-i-o-n

November 14, 1994 8:00 AM UTC

WASHINGTON - As Washington pundits, real estate agents and lobbyists scramble to exploit opportunities presented by the first Republican Congress in 40 years, a number of legislative opportunities potentially favoring the biotechnology industry also are emerging.

The new Congress presents a variety of chances for the biotechnology industry to move from a negative approach to Capitol Hill, fighting battles to block or mitigate bills that could hurt it, to a more positive engagement. There is a good chance the 104th Congress will pass incentives to capital formation, reforms in tort and liabilities law, and intellectual property reforms. ...